InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
5
Disclosed sells
1
T+90 hit rate
67%
T+90 mean return
+62.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by KARINE LIGNEL, Administratrice. Officer active across 2 companies, notably Oncodesign Precision Medicine S.A.. Cumulatively, 6 disclosures have been published. Split: 5 buys · 1 sell. Total volume traded: €1.1m. Activity tracked since 28 April 2022. The latest transaction was filed on 12 December 2022 (Acquisition). Regulator: AMF. All data is openly available.
Declarations6 total
200,000 shares@ €0.82100.0% of flowActionHors plateforme de négociation2022DD876588
Ideal exit: 8 Sept 2023 (T+270)
27,720 shares@ €14.4242.6% of flowActionHors plateforme de négociation2022DD867441
▲
18,480 shares@ €10.0019.7% of flowActionEuronext Paris2022DD865669
Ideal exit: 4 Jul 2023 (T+270)
▲
18,480 shares@ €10.0019.7% of flowActionEuronext Paris2022DD866014
Ideal exit: 4 Jul 2023 (T+270)
9,240 shares@ €9.13489.0% of flowActionEuronext Paris2022DD839952
Ideal exit: 23 Jan 2023 (T+270)
9,240 shares@ €9.13489.0% of flowActionEuronext Growth Paris2022DD841853
Ideal exit: 23 Jan 2023 (T+270)
6 of 6 declarations
About KARINE LIGNEL
Karine Lignel is a Board Member and Deputy Chief Executive Officer at Oncodesign and Oncodesign Precision Medicine S.A. In this role, she participates in the strategic decisions of the board and contributes to the governance of the companies. Karine brings her expertise in research and innovation, which is essential for guiding Oncodesign in its growth initiatives.
